Pay in 4 interest-free payments of $6.85 Learn more
Ships within 48 hours · Estimated delivery Aug 19 - Aug 24
Incretin-Based Drugs Market Trends 2025: GLP-1 & DPP-4 Inhibitor Developments | Leading Companies - AstraZeneca, Boehringer Ingelheim, Inc., Sanofi, Takeda Pharmaceutical Company Limited, Novartis AG DataM Intelligence unveils its latest report on the "Incretin-Based Drugs Market Size 2025," offering an in-depth analysis of market trends, growth drivers, competitive landscape, and regional dynamics
For liraglutide, 21.8% of patients doubled their weight loss, 15.9% lost some additional weight, and 14.2% maintained their loss, with 51.9% in total maintaining or losing more weight
GLP-1 receptor agonists have expanded rapidly beyond their diabetes treatment roots, which creates new gastroparesis risks for a different type of patient
After new remedies are prescribed to an individual, the body may need some time to adjust to a new substance and start working with it properly
US$ 27.47
US$ 24.90
US$ 25.91
/assets/images/provider/photos/2826746.png)
US$ 20.28
